Literature DB >> 25017710

Is bacteriostatic saline superior to normal saline as an echocardiographic contrast agent?

Shaun Cardozo1, Prasad Gunasekaran, Hena Patel, Timothy McGorisk, Mehrdad Toosi, Haroon Faraz, Sandip Zalawadiya, Issa Alesh, Anupama Kottam, Luis Afonso.   

Abstract

Objective data on the performance characteristics and physical properties of commercially available saline formulations [normal saline (NS) vs. bacteriostatic normal saline (bNS)] are sparse. This study sought to compare the in vitro physical properties and in vivo characteristics of two commonly employed echocardiographic saline contrast agents in an attempt to assess superiority. Nineteen patients undergoing transesophageal echocardiograms were each administered agitated regular NS and bNS injections in random order and in a blinded manner according to a standardized protocol. Video time-intensity (TI) curves were constructed from a representative region of interest, placed paraseptally within the right atrium, in the bicaval view. TI curves were analyzed for maximal plateau acoustic intensity (Vmax, dB) and dwell time (DT, s), defined as time duration between onset of Vmax and decay of video intensity below clinically useful levels, reflecting the duration of homogenous opacification of the right atrium. To further characterize the physical properties of the bubbles in vitro, fixed aliquots of similarly agitated saline were injected into a glass well slide-cover slip assembly and examined using an optical microscope to determine bubble diameter in microns (µm) and concentration [bubble count/high power field (hpf)]. A higher acoustic intensity (a less negative dB level), higher bubble concentration and longer DT were considered properties of a superior contrast agent. For statistical analysis, a paired t test was conducted to evaluate the differences in means of Vmax and DT. Compared to NS, bNS administration was associated with superior opacification (video intensity -8.69 ± 4.7 vs. -10.46 ± 4.1 dB, P = 0.002), longer DT (17.3 ± 6.1 vs. 10.2 ± 3.7 s) in vivo and smaller mean bubble size (43.4 vs. 58.6 μm) and higher bubble concentration (1,002 vs. 298 bubble/hpf) in vitro. bNS provides higher intensity and more sustained opacification of the right atrium compared to NS. Higher bubble concentration and stability appear to be additional desirable rheological characteristics favoring bNS as a contrast agent.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25017710     DOI: 10.1007/s10554-014-0493-x

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  19 in total

1.  Stabilization of lysozyme by benzyl alcohol: surface tension and thermodynamic parameters.

Authors:  Monu Kumari Goyal; Ipsita Roy; Aeshna Amin; Uttam Chand Banerjee; Arvind Kumar Bansal
Journal:  J Pharm Sci       Date:  2010-10       Impact factor: 3.534

2.  The usefulness of a 10% air-10% blood-80% saline mixture for contrast echocardiography: Doppler measurement of pulmonary artery systolic pressure.

Authors:  Doo-Soo Jeon; Huai Luo; Takahiro Iwami; Takashi Miyamoto; Andrea V Brasch; James Mirocha; Tasneem Z Naqvi; Robert J Siegel
Journal:  J Am Coll Cardiol       Date:  2002-01-02       Impact factor: 24.094

3.  Superiority of the combination of blood and agitated saline for routine contrast enhancement.

Authors:  S Fan; T Nagai; H Luo; S Atar; T Naqvi; Y Birnbaum; S Lee; R J Siegel
Journal:  J Am Soc Echocardiogr       Date:  1999-02       Impact factor: 5.251

Review 4.  Ultrasound contrast agents: basic principles.

Authors:  F Calliada; R Campani; O Bottinelli; A Bozzini; M G Sommaruga
Journal:  Eur J Radiol       Date:  1998-05       Impact factor: 3.528

5.  The tolerance and safety of intravenously administered benzyl alcohol in methylprednisolone sodium succinate formulations in normal human subjects.

Authors:  E Novak; S S Stubbs; E C Sanborn; R M Eustice
Journal:  Toxicol Appl Pharmacol       Date:  1972-09       Impact factor: 4.219

6.  Parenteral toxicity studies with benzyl alcohol.

Authors:  E T Kimura; T D Darby; R A Krause; H D Brondyk
Journal:  Toxicol Appl Pharmacol       Date:  1971-01       Impact factor: 4.219

7.  Agitated colloid is superior to saline and equivalent to levovist in enhancing tricuspid regurgitation Doppler envelope and in the opacification of right heart chambers: a quantitative, qualitative, and cost-effectiveness study.

Authors:  Hiok C Tan; Kevin C Fung; Leonard Kritharides
Journal:  J Am Soc Echocardiogr       Date:  2002-04       Impact factor: 5.251

8.  American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography.

Authors:  Sharon L Mulvagh; Harry Rakowski; Mani A Vannan; Sahar S Abdelmoneim; Harald Becher; S Michelle Bierig; Peter N Burns; Ramon Castello; Patrick D Coon; Mary E Hagen; James G Jollis; Thomas R Kimball; Dalane W Kitzman; Itzhak Kronzon; Arthur J Labovitz; Roberto M Lang; Joseph Mathew; W Stuart Moir; Sherif F Nagueh; Alan S Pearlman; Julio E Perez; Thomas R Porter; Judy Rosenbloom; G Monet Strachan; Srihari Thanigaraj; Kevin Wei; Anna Woo; Eric H C Yu; William A Zoghbi
Journal:  J Am Soc Echocardiogr       Date:  2008-11       Impact factor: 5.251

9.  Agitated saline versus polygelatine for the echocardiographic assessment of patent foramen ovale.

Authors:  Sonja Cukon Buttignoni; Aliasghar Khorsand; Gerald Mundigler; Jutta Bergler-Klein; Maria Heger; Manfred Zehetgruber; Helmuth Baumgartner; Thomas Binder
Journal:  J Am Soc Echocardiogr       Date:  2004-10       Impact factor: 5.251

10.  Parenteral benzyl alcohol-induced hypersensitivity reaction.

Authors:  J P Wilson; D A Solimando; M S Edwards
Journal:  Drug Intell Clin Pharm       Date:  1986-09
View more
  1 in total

Review 1.  Point-of-care echocardiography for the evaluation of right-to-left cardiopulmonary shunts: a narrative review.

Authors:  Tim Montrief; Stephen Alerhand; André Denault; Jeffrey Scott
Journal:  Can J Anaesth       Date:  2020-09-17       Impact factor: 5.063

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.